Press Releases

and/or
567 News Releases found
Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the <i>New England Journal of Medicine</i>.
A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™).
Colonoscopy Prevents Deaths From Colon Cancer
For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease. Patients in the study were evaluated for up to 23 years after having the procedure, providing the longest follow-up results to date.
Pictured: Cycle for Survival
More than 10,000 people nationwide will participate in Memorial Sloan Kettering Cancer Center’s sixth annual Cycle for Survival event taking place this February at Equinox clubs in New York City, Long Island, Washington D.C., Chicago, San Francisco, and Los Angeles.
Media Advisory
The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.
As a tribute to Memorial Sloan Kettering Board member Josephine “Josie” Robertson, Memorial Sloan Kettering has joined with The Robertson Foundation to undertake two high-profile initiatives — the Josie Robertson Surgery Center and the Josie Robertson Investigators Program — made possible by a $50 million commitment from The Robertson Foundation.
Media Advisory
A Memorial Sloan Kettering Cancer Center study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation more effective and safe.
Pictured: David Solit
Media Advisory
Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.
Two nurses talking to each other
A five-year grant of more than $1.4 million will fund a program to train nurses in helping survivors achieve the best possible quality of life after cancer.
Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented biennially by Memorial Sloan Kettering to honor promising scientists under the age of 46.